Cooper Stock Price, News & Analysis

CooperCompanies (NYSE: COO) will release its Q1 2022 financial results on March 3, 2022, at 4:15 PM ET. Following the release, a conference call will be held at 5:00 PM ET to discuss results and corporate developments. Participants can join via dial-in or through the Company's website. A recording will be available after the call until March 10, 2022. CooperCompanies focuses on medical devices, operating through two units: CooperVision and CooperSurgical, and employs over 12,000 individuals globally.

CooperCompanies (NYSE: COO) will present at the J.P. Morgan Healthcare Conference on January 11, 2022, at 2:15 PM ET. Al White, President and CEO, will lead the virtual session. Interested parties can access a live webcast on the Investor Relations section of the company's website, which will be available for 30 days post-event. CooperCompanies focuses on medical devices through its units, CooperVision and CooperSurgical, and employs over 12,000 people globally.

CooperCompanies (NYSE: COO) has finalized the acquisition of Generate Life Sciences for around $1.6 billion. This acquisition enhances Cooper's offerings in fertility treatments, cryopreservation, and stem cell storage. Cooper's President and CEO, Al White, expressed enthusiasm for integrating Generate's employees into the Cooper family, aiming to bolster services for fertility clinics and Ob/Gyns. To finance the acquisition, Cooper has secured a $1.5 billion non-amortizing senior unsecured term loan.

CooperCompanies (NYSE: COO) has scheduled its annual meeting of stockholders for March 16, 2022. Stockholders who are recorded by January 20, 2022, can vote on key matters, including the election of directors. The company is divided into two main business units: CooperVision, focusing on vision care products, and CooperSurgical, which specializes in women’s and family health. Headquartered in San Ramon, CA, Cooper operates globally with over 12,000 employees and products in more than 100 countries.

CooperCompanies (NYSE: COO) has declared a semi-annual dividend of 3 cents per share, as part of its ongoing annual dividend plan. This dividend will be payable on February 9, 2022, to stockholders recorded by January 21, 2022. The company operates two business units: CooperVision, which focuses on vision care products, and CooperSurgical, dedicated to women's health and medical devices. With over 12,000 employees and products available in over 100 countries, Cooper continues to enrich the lives of its customers globally.

CooperCompanies (NYSE: COO) reported strong financial results for Q4 and FY 2021. Revenue rose 11% YoY to $759.1 million in Q4, with full-year revenue increasing 20% to $2.92 billion. GAAP diluted EPS for Q4 stood at $2.21 (up 35%) and $59.16 for FY 2021 (up 1,131%). The company achieved record annual revenue and profits, with a gross margin of 66% in Q4. For FY 2022, the company forecasts revenue between $3.03 billion and $3.09 billion, indicating growth. CEO Al White emphasized continued market share gain in contact lenses and fertility sectors.

CooperCompanies (NYSE: COO) announced key leadership changes to enhance organizational growth. Effective February 1, 2022, Dan McBride, currently EVP and COO, will expand his role to include global leadership of human resources, legal, and corporate strategy, while maintaining oversight of CooperVision. Jerry Warner, previously EVP for Americas and Global Commercial Functions, will be promoted to President of CooperVision, managing all global functions within the unit. This restructuring aims to leverage industry expertise and strengthen strategic direction amid the company's growth trajectory.

Generate Life Sciences announces its agreement to be acquired by CooperCompanies (NYSE: COO), aiming to enhance CooperSurgical's capabilities in women's health and fertility. This strategic acquisition allows Generate to leverage CooperSurgical's global network in over 100 countries, increasing access to innovative reproductive and genetic services. Generate's products complement CooperSurgical's current offerings, potentially leading to improved patient options in assisted reproductive technology. The transaction awaits regulatory approval, with closing anticipated in Cooper's Fiscal first quarter.

GI Partners has signed a definitive agreement to sell Generate Life Sciences, a leader in reproductive and newborn stem cell services, to CooperCompanies (NYSE:COO). Generate Life Sciences, formed in 2018, combines industry leaders California Cryobank Life Sciences and Cord Blood Registry, serving nearly one million families globally. The transaction, which is subject to customary closing conditions, is expected to finalize in December 2021. This acquisition aims to enhance CooperCompanies' offerings in reproductive and genetic services, further expanding its global reach.